Overview
This study focused on EBV-positive diffuse large B-cell lymphoma (EBV+ DLBCL), a rare subtype of lymphoma, which makes up less than 5% of all large B-cell lymphomas in the U.S. By analyzing data from over 5,900 patients from the Flatiron Health electronic health record-derived de-identified database, the research compared the characteristics and outcomes of EBV+ DLBCL with those of DLBCL not otherwise specified (NOS).
The findings revealed that while patients received similar treatments, those with EBV+ DLBCL had significantly worse survival rates, emphasizing the need for better treatment strategies to improve outcomes for this specific patient group
Why this matters
This study improved our understanding and provided insights into treatment patterns and outcomes for a rare patient population. By analyzing real-world data, researchers were able to highlight gaps in current therapies likely not possible to study through traditional clinical trial methods.